Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12

NCT02483312 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02483312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02483312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 30, 2015
Completion date
August 31, 2026
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia